Adjusting Power Calculations and Trial Sample Size for Treatment Resistance
Tepekule, B.
Show abstract
Statistical calculations for clinical trials traditionally assume that if a treatment fails, it fails for mechanistic reasons--the drug itself is ineffective. However, patients may be treatment-resistant, rendering them unable to benefit from an otherwise effective treatment. This creates an identifiability problem: a null hypothesis that we fail to reject can indicate either an ineffective treatment, or an effective treatment tested in a population dominated by treatment-resistant subjects. However, the strategy to administer the drug should be different for these cases. Here we present a simple way to adjust the sample size of a randomized controlled trial to account for the anticipated level of treatment resistance to reach a certain statistical power. We show that the resistant-adjusted population size exponentially increases with the anticipated resistance prevalence, whereas power decreases almost linearly for a given population size as the resistance prevalence increases.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimating Counterfactual Placebo HIV Incidence in HIV Prevention Trials Without Placebo Arms Based on Markers of HIV Exposure 93%
- Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials 91%
- Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative 90%
Similar papers in this journal
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 92%
- Significant Relaxation of SARS-CoV-2-Targeted Non-Pharmaceutical Interventions Will Result in Profound Mortality: A New York State Modelling Study 91%
- Clinical Trials for Wolfram Syndrome Neurodegeneration: Novel Design, Endpoints, and Analysis Models 90%
Similar papers in this journal
- Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials 92%
- Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes 91%
- Real-world Effectiveness of BNT162b2 in Children and Adolescents in Preventing Infection and Severe Diseases with SARS-CoV-2 During the Delta and Omicron Periods: Findings from Trial Emulation Using an EHR-based Cohort 88%
Similar papers in this journal
- Infection control strategies in essential industries: using COVID-19 in the food industry to model economic and public health trade-offs 90%
- Importance of epidemic severity and vaccine mode of action and availability for delaying the second vaccine dose 90%
- Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study 90%
Similar papers in this journal
- Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial 89%
- Vaccine-Elicited Antibody Responses to Influenza H3N2 Subclade K 85%
- Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection 85%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.